GLIOGUIDE SIGNED
Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GLIOGUIDE project word cloud
Explore the words cloud of the GLIOGUIDE project. It provides you a very rough idea of what is the project "GLIOGUIDE" about.
Project "GLIOGUIDE" data sheet
The following table provides information about the project.
| Coordinator |
TARTU ULIKOOL
Organization address contact info |
| Coordinator Country | Estonia [EE] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2017-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-06-01 to 2019-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | TARTU ULIKOOL | EE (TARTU) | coordinator | 150˙000.00 |
Map
Project objective
Glioblastoma (GBM), is the most aggressive form of primary brain cancer and is diagnosed in 22,000 people per year in the EU. GBM is the most aggressive primary brain cancer and, by annual incidence, the most common type of malignant brain tumour. Despite aggressive treatment, the cancer always recurs. The average survival after diagnosis is 12 to 15 months, with less than 3% to 5% of patients surviving longer than 5 years. The current standard of care extends overall survival to ~14 -16 months. Current valuation of the global GBM treatment market is estimated to be €615 million per year, and it is predicted to increase to over €3.08 billion by 2024 (compound annual growth rate of 17%), based on the projected approval of new therapies including Opdivo and Optune. The main aim of this ERC PoC proposal is to probe the commercial viability of two types of tumour-targeted payload hybrids, one as an improved chemotherapeutic treatment, and the other as a precision-guided imaging agent for PET/MRI-based diagnosis. Our goal is for the former to become the clinician’s chemotherapy of choice in the adjuvant phase of GBM treatment; and for the latter to be incorporated into PET and MR-imaging procedures as a method for identifying and diagnosing GBM, as well as a companion test for stratification of patients for therapy.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Prakash Lingasamy, Allan Tobi, Maarja Haugas, Hedi Hunt, Päärn Paiste, Toomas Asser, Tõnu Rätsep, Venkata Ramana Kotamraju, Rolf Bjerkvig, Tambet Teesalu Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery published pages: 119373, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2019.119373 |
Biomaterials 219 | 2020-02-06 |
| 2020 |
Giulia Torrieri, Flavia Fontana, PatrÃcia Figueiredo, Zehua Liu, Mónica P. A. Ferreira, Virpi Talman, João P. Martins, Manlio Fusciello, Karina Moslova, Tambet Teesalu, Vincenzo Cerullo, Jouni Hirvonen, Heikki Ruskoaho, Vimalkumar Balasubramanian, Hélder A. Santos Dual-peptide functionalized acetalated dextran-based nanoparticles for sequential targeting of macrophages during myocardial infarction published pages: 2350-2358, ISSN: 2040-3364, DOI: 10.1039/c9nr09934d |
Nanoscale 12/4 | 2020-02-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOGUIDE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLIOGUIDE" are provided by the European Opendata Portal: CORDIS opendata.